Market revenue in 2023 | USD 22,973.7 million |
Market revenue in 2030 | USD 52,685.8 million |
Growth rate | 12.6% (CAGR from 2023 to 2030) |
Largest segment | Personalized nutrition & wellness |
Fastest growing segment | PM Therapeutics |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | PM Diagnostics, PM Therapeutics, Personalized Medical Care, Personalized Nutrition & Wellness |
Key market players worldwide | GE HealthCare Technologies Inc Common Stock, Illumina Inc, Asure Software Inc, Abbott Laboratories, Danaos Corp, Exact Sciences Corp, Danaher Corp, Amgen Inc, Qiagen NV, Exagen Inc Ordinary Shares, Quest Diagnostics Inc, Biogen Inc, Genelux Corp, International Business Machines Corp, Genentech, 23andMe Holding Co Class A |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to personalized medicine market will help companies and investors design strategic landscapes.
Personalized nutrition & wellness was the largest segment with a revenue share of 33.08% in 2023. Horizon Databook has segmented the China personalized medicine market based on pm diagnostics, pm therapeutics, personalized medical care, personalized nutrition & wellness covering the revenue growth of each sub-segment from 2018 to 2030.
Government support and involvement in cross-border international collaborations for preventive & personalized medicine is expected to fuel market growth. Considering this factor, the Chinese government had planned to make personalized medicine a part of its 5-Year Plan for 2016-2020 as it prioritizes genomics for better health care outcomes.
Wide applications of cell & gene therapies in China also play a key role in the progression of precision medicine. With regard to this, GE Healthcare developed three KUBio manufacturing facilities for Chinese biopharmaceutical companies in 2018, which expanded the company’s FlexFactory offerings in China to meet the manufacturing requirements of cell & gene therapies.
Horizon Databook provides a detailed overview of country-level data and insights on the China personalized medicine market , including forecasts for subscribers. This country databook contains high-level insights into China personalized medicine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account